Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis

  • Gensicke H
  • Leppert D
  • Yaldizli O
 et al. 
  • 5


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Multiple sclerosis (MS) is an inflammatory and degenerative disease leading to demyelination and axonal damage in the CNS. Autoimmunity plays a central role in MS pathogenesis. Per definition, monoclonal antibodies are recombinant biological compounds with a well defined target, thus carrying the promise of targeting pathogenic cells or molecules with high specificity, avoiding undesired off-target effects. Natalizumab was the first monoclonal antibody to be approved for the treatment of MS. Several other monoclonal antibodies are in development and have demonstrated promising efficacy in phase II studies. They can be categorized according to their mode of action into compounds targeting (i) leukocyte migration into the CNS (natalizumab); (ii) cytolytic antibodies (rituximab, ocrelizumab, ofatumumab, alemtuzumab); or (iii) antibodies and recombinant proteins targeting cytokines and chemokines and their receptors (daclizumab, ustekinumab, atacicept, tabalumab [Ly-2127399], secukinumab [AIN457]). In this review, we discuss the specific molecular targets, clinical efficacy and safety of these compounds and discuss criteria to anticipate the position of monoclonal antibodies in the diversifying armamentarium of MS therapy in the coming years.

Author-supplied keywords

  • Animals
  • Antibodies, Monoclonal, Humanized/*administration
  • Antibodies, Monoclonal, Murine-Derived/*administra
  • Antibodies, Monoclonal/*administration & dosage
  • Drug Delivery Systems/methods
  • Humans
  • Multiple Sclerosis/*immunology/*therapy
  • Recombinant Proteins/administration & dosage
  • Treatment Outcome

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in


  • H Gensicke

  • D Leppert

  • O Yaldizli

  • R L Lindberg

  • M Mehling

  • L Kappos

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free